Harvard Bioscience Past Earnings Performance

Past criteria checks 0/6

Harvard Bioscience's earnings have been declining at an average annual rate of -14%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 0.8% per year.

Key information

-14.0%

Earnings growth rate

-10.4%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate-0.8%
Return on equity-21.8%
Net Margin-14.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Harvard Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:HBI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2498-144511
30 Jun 24101-114611
31 Mar 24107-94612
31 Dec 23112-34712
30 Sep 23113-34711
30 Jun 23114-54711
31 Mar 23115-24812
31 Dec 22113-104912
30 Sep 22118-75112
30 Jun 22121-45012
31 Mar 22121-64912
31 Dec 2111904711
30 Sep 21117-24510
30 Jun 21111-3439
31 Mar 21105-4419
31 Dec 20102-8419
30 Sep 20102-7429
30 Jun 20105-84410
31 Mar 20112-74510
31 Dec 19116-54611
30 Sep 19119-24711
30 Jun 1912004611
31 Mar 19122-14711
31 Dec 18121-44611
30 Sep 18109-8429
30 Jun 1899-8398
31 Mar 1886-7357
31 Dec 1777-2336
30 Sep 1782-3345
30 Jun 1788-4365
31 Mar 1796-4395
31 Dec 16105-4415
30 Sep 16106-20416
30 Jun 16107-19426
31 Mar 16110-18416
31 Dec 15109-19406
30 Sep 15111-2406
30 Jun 151100386
31 Mar 151090366
31 Dec 141092355
30 Sep 141062344
30 Jun 141061354
31 Mar 141051354
31 Dec 131051354

Quality Earnings: HBI is currently unprofitable.

Growing Profit Margin: HBI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HBI is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.

Accelerating Growth: Unable to compare HBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HBI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).


Return on Equity

High ROE: HBI has a negative Return on Equity (-21.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Harvard Bioscience, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Bruce JacksonBenchmark Company
Paul KnightJanney Montgomery Scott LLC